386 related articles for article (PubMed ID: 27058531)
1. Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.
Shaikh AB; Li F; Li M; He B; He X; Chen G; Guo B; Li D; Jiang F; Dang L; Zheng S; Liang C; Liu J; Lu C; Liu B; Lu J; Wang L; Lu A; Zhang G
Int J Mol Sci; 2016 Apr; 17(4):506. PubMed ID: 27058531
[TBL] [Abstract][Full Text] [Related]
2. Role of TKI for Metastatic Osteogenic Sarcoma.
Duffaud F
Curr Treat Options Oncol; 2020 Jun; 21(8):65. PubMed ID: 32601895
[TBL] [Abstract][Full Text] [Related]
3. Is CDK9 a promising target for both primary and metastatic osteosarcoma?
Qin JJ
EBioMedicine; 2019 Feb; 40():27-28. PubMed ID: 30651218
[No Abstract] [Full Text] [Related]
4. MAPK pathways regulation by DUSP1 in the development of osteosarcoma: Potential markers and therapeutic targets.
Lopes LJS; Tesser-Gamba F; Petrilli AS; de Seixas Alves MT; Garcia-Filho RJ; Toledo SRC
Mol Carcinog; 2017 Jun; 56(6):1630-1641. PubMed ID: 28112450
[TBL] [Abstract][Full Text] [Related]
5. Receptor tyrosine kinases in osteosarcoma: not just the usual suspects.
Rettew AN; Getty PJ; Greenfield EM
Adv Exp Med Biol; 2014; 804():47-66. PubMed ID: 24924168
[TBL] [Abstract][Full Text] [Related]
6. Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole.
Liao S; Ruiz Y; Gulzar H; Yelskaya Z; Ait Taouit L; Houssou M; Jaikaran T; Schvarts Y; Kozlitina K; Basu-Roy U; Mansukhani A; Mahajan SS
PLoS One; 2017; 12(2):e0171256. PubMed ID: 28231291
[TBL] [Abstract][Full Text] [Related]
7. The anti-osteosarcoma cell activity by a mTORC1/2 dual inhibitor RES-529.
Hu X; Wang Z; Chen M; Chen X; Liang W
Biochem Biophys Res Commun; 2018 Mar; 497(2):499-505. PubMed ID: 29432734
[TBL] [Abstract][Full Text] [Related]
8. Osteosarcoma Pathogenesis Leads the Way to New Target Treatments.
Fernandes I; Melo-Alvim C; Lopes-Brás R; Esperança-Martins M; Costa L
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467481
[TBL] [Abstract][Full Text] [Related]
9. Blocking miR-27a-3p sensitises Taxol resistant osteosarcoma cells through targeting Fbxw7.
Lu B; Feng Z; Fan B; Shi Y
Bull Cancer; 2021 Jun; 108(6):596-604. PubMed ID: 33863546
[TBL] [Abstract][Full Text] [Related]
10. Current Status and Prospects of Targeted Therapy for Osteosarcoma.
Hu Z; Wen S; Huo Z; Wang Q; Zhao J; Wang Z; Chen Y; Zhang L; Zhou F; Guo Z; Liu H; Zhou S
Cells; 2022 Nov; 11(21):. PubMed ID: 36359903
[TBL] [Abstract][Full Text] [Related]
11. Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma.
Jiang H; Zeng Z
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):255-61. PubMed ID: 26514724
[TBL] [Abstract][Full Text] [Related]
12. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
[TBL] [Abstract][Full Text] [Related]
13. Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives.
Fleuren ED; Versleijen-Jonkers YM; Boerman OC; van der Graaf WT
Biochim Biophys Acta; 2014 Apr; 1845(2):266-76. PubMed ID: 24582852
[TBL] [Abstract][Full Text] [Related]
14. Targeting the VEGF Pathway in Osteosarcoma.
Assi T; Watson S; Samra B; Rassy E; Le Cesne A; Italiano A; Mir O
Cells; 2021 May; 10(5):. PubMed ID: 34069999
[TBL] [Abstract][Full Text] [Related]
15. Autophagy regulation by microRNAs: Novel insights into osteosarcoma therapy.
Jamali Z; Taheri-Anganeh M; Shabaninejad Z; Keshavarzi A; Taghizadeh H; Razavi ZS; Mottaghi R; Abolhassan M; Movahedpour A; Mirzaei H
IUBMB Life; 2020 Jul; 72(7):1306-1321. PubMed ID: 32233112
[TBL] [Abstract][Full Text] [Related]
16. The possible role of insulin-like growth factor-1 in osteosarcoma.
Li YS; Liu Q; He HB; Luo W
Curr Probl Cancer; 2019 Jun; 43(3):228-235. PubMed ID: 30217668
[TBL] [Abstract][Full Text] [Related]
17. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature.
PosthumaDeBoer J; Witlox MA; Kaspers GJ; van Royen BJ
Clin Exp Metastasis; 2011 Jun; 28(5):493-503. PubMed ID: 21461590
[TBL] [Abstract][Full Text] [Related]
18. Molecular Signaling Pathways as Potential Therapeutic Targets in Osteosarcoma.
Dana PM; Sadoughi F; Asemi Z; Yousefi B
Curr Med Chem; 2022; 29(25):4436-4444. PubMed ID: 35139778
[TBL] [Abstract][Full Text] [Related]
19. Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.
Wang W; Zhao HF; Yao TF; Gong H
Invest New Drugs; 2019 Feb; 37(1):175-183. PubMed ID: 30353245
[TBL] [Abstract][Full Text] [Related]
20. Molecular targeted therapies in advanced or metastatic chordoma patients: facts and hypotheses.
Lebellec L; Aubert S; Zaïri F; Ryckewaert T; Chauffert B; Penel N
Crit Rev Oncol Hematol; 2015 Jul; 95(1):125-31. PubMed ID: 25682222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
